Differential responsiveness to immunoablative therapy in refractory rheumatoid arthritis is associated with level and avidity of anti-cyclic citrullinated protein autoantibodies: A case study

Arthritis Research and Therapy

Volumn 9, Issue 5, 2007, Pages

  Teng, Y K Onno ^a   Verburg, Robert J ^a   Verpoort, Kirsten N ^a   Diepenhorst, Gwendolyn M P ^b   Bajema, Ingeborg M ^a   van Tol, Maarten J D ^a   Jol van der Zijde, Els C M ^a   Toes, Rene E M ^a   Huizinga, Tom W J ^a   van Laar, Jacob M ^c  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b SANQUIN RESEARCH   (Netherlands)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; AUTOANTIBODY; C REACTIVE PROTEIN; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; DISEASE MODIFYING ANTIRHEUMATIC DRUG; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; PHOSPHORYLCHOLINE; RHEUMATOID FACTOR; RUBELLA ANTIBODY; TETANUS ANTIBODY; TETANUS TOXOID; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; CITRULLINE; IMMUNOSUPPRESSIVE AGENT; PROTEIN;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTHROSCOPY; ARTICLE; AUTOIMMUNITY; CLINICAL ARTICLE; DISEASE COURSE; DRUG MEGADOSE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; JOINT BIOPSY; MALE; PROTEIN BLOOD LEVEL; RELAPSE; RHEUMATOID ARTHRITIS; TREATMENT RESPONSE; COMPARATIVE STUDY; FOLLOW UP; IMMUNOLOGY; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; CITRULLINE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PROTEINS; TETANUS TOXOID; TREATMENT OUTCOME;

EID: 36849066403     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar2309     Document Type: Article

References (39)

1. Maetzel A, Wong A, Strand V, Tugwell P, Wells G, Bombardier C: Meta-analysis of treatment termination rates among rheumatoid arthritis patients receiving disease-modifying anti-rheumatic drugs. Rheumatology (Oxford) 2000, 39:975-981. 10.1093/rheumatology/39.9.975 10986302
2. Aletaha D, Smolen JS: Effectiveness profiles and dose dependent retention of traditional disease modifying antirheumatic drugs for rheumatoid arthritis. An observational study. J Rheumatol 2002, 29:1631-1638. 12180721
3. van der Kooij SM, Vries-Bouwstra JK, Goekoop-Ruiterman YP, van Zeben D, Kerstens PJ, Gerards AH, van Groenendael JH, Hazes JM, Breedveld FC, Allaart CF, Dijkmans BA: Limited efficacy of conventional DMARDs after initial methotrexate failure in patients with recent onset rheumatoid arthritis treated according to the Disease Activity Score. Ann Rheum Dis 2007, 66:1356-1362. 10.1136/ard.2006.066662 17293364
4. Burt RK, Marmont A, Oyama Y, Slavin S, Arnold R, Hiepe F, Fassas A, Snowden J, Schuening F, Myint H: Randomized controlled trials of autologous hematopoietic stem cell transplantation for autoimmune diseases: The evolution from myeloablative to lymphoablative transplant regimens. Arthritis Rheum 2006, 54:3750-3760. 10.1002/art.22256 17133541
5. Tyndall A, Saccardi R: Haematopoietic stem cell transplantation in the treatment of severe autoimmune disease: Results from phase I/II studies, prospective randomized trials and future directions. Clin Exp Immunol 2005, 141:1-9. 1809422 15958063 10.1111/j.1365-2249.2005.02806.x
6. Lipsky PE: Systemic lupuA erythematosus: an autoimmune disease of B cell hyperactivity. Nat Immunol 2001, 2:764-766. 10.1038/ni0901-764 11526379
7. Avouac J, Gossec L, Dougados M: Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: A systematic literature review. Ann Rheum Dis 2006, 65:845-851. 10.1136/ ard.2006.051391 16606649
8. Nishimura K, Sugiyama D, Kogata Y, Tsuji G, Nakazawa T, Kawano S, Saigo K, MorinoDu A, Koshiba M, Kuntz KM: Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med 2007, 146:797-808. 17548411
9. Kurien BT, Scofield RH: Autoantibody determination in the diagnosis of systemic lupus erythematosus. Scand J Immunol 2006, 64:227-235. 10.1111/ j.1365-3083.2006.01819.x 16918691
10. Lyons R, Narain S, Nichols C, Satoh M, Reeves WH: Effective use of autoantibody tests in the diagnosis of systemic autoimmune disease. Ann N Y Acad Sci 2005, 1050:217-228. 10.1196/annals.1313.023 16014537
11. Harris ML, Rosen A: AutTimmunity in scleroderma: the origin, pathogenetic role, and clinical significance of autoantibodies. Curr Opin Rheumatol 2003, 15:778-784. 10.1097/00002281-200311000-00016 14569210
12. Hietarinta M, Lassila O: Clinical significance of antinuclear antibodies in systemic rheumatic diseases. Ann Med 1996, 28:283-291. 8862680
13. van der Helm-van Mil AH, Verpoort KN, Breedveld FC, Toes RE, Huizinga TW: Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis. Arthritis Res Ther 2005, 7:R949-R958. 1257421 16207336 10.1186/ar1767
14. Swaak T, Smeenk R: Clinical significance of antibodies to double stranded DNA (dsDNA) for systemic lupus erythematosus (SLE). Clin Rheumatol 1987, Suppl 1:56-73
15. Nielen MM, van Schaardenburg D, Reesink HW, van de Stadt RJ, van Der Horst-Bruinsma IE, de Koning MH, Habibuw MR, Vandenbroucke JP, Dijkmans BA: Specific autoantibodies precede the symptoms of rheumatoid arthritis: A study of serial measurements in blood donors. Arthritis Rheum 2004, 50:380-386. 10.1002/art.20018 14872479
16. Berglin E, Johansson T, Sundin U, Jidell E, Wadell G, Hallmans G, Rantapaa-Dahlqvist S: Radiological outcome in rheumatoid arthritis is predicted by presence of antibodies against cyclic citrullinated peptide before and at disease onset, and by IgA-RF at disease onset. Ann Rheum Dis 2006, 65:453-458. 10.1136/ard.2005.041376 16176994
17. Braun-Moscovici Y, Markovits D, Zinder O, Schapira D, Rozin A, Ehrenburg M, Dain L, Hoffer E, Nahir AM, Balbir-Gurman A: Anti-cyclic citrullinated protein antibodies as a predictor of response to anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis. J Rheumatol 2006, 33:497-500. 16511906
18. Martin F, Chan AC: B cell iEmunobiology in disease: evolving concepts from the clinic. Annu Rev Immunol 2006, 24:467-496. 10.1146/ annurev.immunol.24.021605.090517 16551256
19. Mikuls TR, O'Dell JR, Stoner JA, Parrish LA, Arend WP, Norris JM, Holers VM: Association of rheumatoid arthritis treatment response and disease duration with declines in serum levels of IgM rheumatoid factor and anti-cyclic citrullinated peptide antibody. Arthritis Rheum 2004, 50:3776-3782. 10.1002/art.20659 15593224
20. Manz RA, Thiel A, Radbruch A: Lifetime of plasma cells in the bone marrow. Nature 1997, 388:133-134. 10.1038/40540 9217150
21. Hoyer BF, Moser K, Hauser AE, Peddinghaus A, Voigt C, Eilat D, Radbruch A, Hiepe F, Manz RA: Short-lived plasmablasts and long-lived plasma cells contribute to chronic humoral autoimmunity in NZB/W mice. J Exp Med 2004, 199:1577-1584. 10.1084/jem.20040168 15173206
22. Verpoort KN, Jol-van der Zijde CM, Papendrecht-van der Voort EA, Ioan-Facsinay A, Drijfhout JW, van Tol MJ, Breedveld FC, Huizinga TW, Toes RE: Isotype distribution of anti-cyclic citrullinated peptide antibodies in undifferentiated arthritis and rheumatoid arthritis reflects an ongoing immune response. Arthritis Rheum 2006, 54:3799-3808. 10.1002/art.22279 17133560
23. Reparon-Schuijt CC, van Esch WJ, van Kooten C, Schellekens GA, de Jong BA, van Venrooij WJ, Breedveld FC, Verweij CL: Secretion of anti-citrulline-containing peptide antibody by B lymphocytes in rheumatoid arthritis. Arthritis Rheum 2001, 44:41-47. 10.1002/ 1529-0131(200101)44:1<41::AID-ANR6>3.0.CO;2-0 11212174
24. Storek J, Ferrara S, Rodriguez C, Saxon A: Recovery of mononuclear cell subsets after bone marrow transplantation: Overabundance of CD4+CD8+ dual-positive T cells reminiscent of ontogeny. J Hematother 1992, 1:303-316. 1345675
25. Storek J, Ferrara S, Ku N, Giorgi JV, Champlin RE, Saxon A: B cell reconstitution after human bone marrow transplantation: Recapitulation of ontogeny?. Bone Marrow Transplant 1993, 12:387-398. 8275039
26. Verburg RJ, Kruize AA, van den Hoogen FH, Fibbe WE, Petersen EJ, Preijers F, Sont JK, Barge RM, Bijlsma JW, van de Putte LB: High-dose chemotherapy and autologous hematopoietic stem cell transplantation in patients with rheumatoid arthritis: Results of an open study to assess feasibility, safety, and efficacy. Arthritis Rheum 2001, 44:754-760. 10.1002/1529-0131(200104)44:4<754::AID-ANR131>3.0.CO;2-N 11315914
27. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31:315-324. 10.1002/art.1780310302 3358796
28. van der Heijde DM, van 't HM, van Riel PL, van de Putte LB: Development of a disease activity score based on judgment in clinical practice by rheumatologists. J Rheumatol 1993, 20:579-581. 8478878
29. van Oosterhout M, Levarht EW, Sont JK, Huizinga TW, Toes RE, van Laar JM: Clinical efficacy of infliximab plus methotrexate in DMARD naive and DMARD refractory rheumatoid arthritis is associated with decreased synovial expression of TNF alpha and IL18 but not CXCL12. Ann Rheum Dis 2005, 64:537-543. 10.1136/ard.2004.024927 15769913
30. Kraan MC, Haringman JJ, Post WJ, Versendaal J, Breedveld FC, Tak PP: Immunohistological analysis of synovial tissue for differential diagnosis in early arthritis. Rheumatology (Oxford) 1999, 38:1074-1080. 10.1093/rheumatology/38.11.1074 10556258
31. Tak PP, Smeets TJ, Daha MR, Kluin PM, Meijers KA, Brand R, Meinders AE, Breedveld FC: Analysis of the synovial cell infiltrate in early rheumatoid synovial tissue in relation to local disease activity. Arthritis Rheum 1997, 40:217-225. 10.1002/art.1780400206 9041933
32. van Esch WJ, Reparon-Schuijt CC, Levarht EW, van Kooten C, Breedveld FC, Verweij CL: Differential requirements for induction of total immunoglobulin and physiological rheumatoid factor production by human peripheral blood B cells. Clin Exp Immunol 2001, 123:496-504. 1906001 11298139 10.1046/j.1365-2249.2001.01475.x
33. Padilla ND, Ciurana C, van Oers J, Ogilvie AC, Hack CE: Levels of natural IgM antibodies against phosphorylcholine in healthy individuals and in patients undergoing isolated limb perfusion. J Immunol Methods 2004, 293:1-11. 10.1016/j.jim.2004.06.011 15541272
34. Kroon FP, van Tol MJ, Jol-van der Zijde CM, van Furth R, van Dissel JT: Immunoglobulin G (IgG) subclass distribution and IgG1 avidity of antibodies in human immunodeficiency virus-infected individuals after revaccination with tetanus toxoid. Clin Diagn Lab Immunol 1999, 6:352-355. 103722 10225835
35. van Gestel AM, Prevoo ML, 't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL: Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 1996, 39:34-40. 10.1002/art.1780390105 8546736
36. Newkirk MM, Fournier MJ, Shiroky J: Rheumatoid factor avidity in patients with rheumatoid arthritis: Identification of pathogenic RFs which correlate with disease parameters and with the gal(0) glycoform of IgG. J Clin Immunol 1995, 15:250-257. 10.1007/BF01540882 8537469
37. Harris EN, Pierangeli S: Anticardiolipin antibodies: specificity and function. Lupus 1994, 3:217-222. 7804305
38. Alessandri C, Bombardieri M, Papa N, Cinquini M, Magrini L, Tincani A, Valesini G: Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNFalpha therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement. Ann Rheum Dis 2004, 63:1218-1221. 1754775 15361374 10.1136/ard.2003.014647
39. Ronnelid J, Wick MC, Lampa J, Lindblad S, Nordmark B, Klareskog L, van Vollenhoven RF: Longitudinal analysis of citrullinated protein/peptide antibodies (anti-CP) during 5 year follow up in early rheumatoid arthritis: Anti-CP status predicts worse disease activity and greater radiological progression. Ann Rheum Dis 2005, 64:1744-1749. 10.1136/ ard.2004.033571 15843452